PHMB.US Pharmacom Biovet Inc
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -308.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2003.
Is PHMB.US undervalued?
Graham numberThe Graham number of Pharmacom Biovet Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pharmacom Biovet Inc fundamental analysis
No fundamental analysis for Pharmacom Biovet Inc yet.
Pharmacom Biovet Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pharmacom Biovet Inc
PharmaCom BioVet, Inc. focuses on operating a network of companion animal cancer treatment centers in the United States. The company focuses on developing bone marrow transplantation and other cancer treatment procedures to benefit companion animals that are diagnosed with lymphoma, other different types of cancers, and other diseases that are incurable. It has licensed a series of proprietary devices and compounds that would reduce suffering in animals with cancer. The comp…
Full company profilePharmacom Biovet Inc financial statements
2003 annualized: Fiscal year 2003 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2003, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pharmacom Biovet Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2000 | 2001 | 2002 | 2003 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -18.2M | -311K | -556K | -414K |
| Net Income | -18.2M | -311K | -556K | -414K |
| Balance Sheet | ||||
| Total Assets | 4.50K | 4.50K | 112K | 163K |
| Total Liabilities | 1.08K | 4.58K | 61.5K | 28.5K |
| Shareholders' Equity | 3.43K | -75.00 | 50.8K | 134K |
| Cash Flow | ||||
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 |
| Ratios | ||||
| ROE | -530,742.9% | - | -1,094.3% | -308.3% |
| ROA | -403,954.3% | -6,917.8% | -495.0% | -254.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Pharmacom Biovet Inc dividends
Pharmacom Biovet Inc has not paid dividends in the last 3 fiscal years.
Last stock split: 1:15 on Sep 10, 2008.
Who owns Pharmacom Biovet Inc
Ownership data of Pharmacom Biovet Inc is not available yet.
Pharmacom Biovet Inc company profile
- Company name
- Pharmacom Biovet Inc
- Ticker
- PHMB.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- December
- Address
- 6040-A Six Forks Road, Raleigh, NC, United States, 27609
- Phone
- 919 604 4887
- Website
- -
About Pharmacom Biovet Inc
PharmaCom BioVet, Inc. focuses on operating a network of companion animal cancer treatment centers in the United States. The company focuses on developing bone marrow transplantation and other cancer treatment procedures to benefit companion animals that are diagnosed with lymphoma, other different types of cancers, and other diseases that are incurable. It has licensed a series of proprietary devices and compounds that would reduce suffering in animals with cancer. The company was formerly known as ABV Gold Inc. and changed its name to PharmaCom BioVet, Inc. in August 2008. PharmaCom BioVet, Inc. was incorporated in 1995 and is headquartered in Raleigh, North Carolina.
Pharmacom Biovet Inc management
3- Mr. Ira FrohmanPresident, Secretary, Treasurer and Director
- Mr. Steve A. YorkVice President of Operations & Marketing and Director
- Mr. Dino Paolucci Jr.Vice President of D Mecatronics and Director